Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night.

The article highlights J&J, UnitedHealth, and McKesson as defensive dividend growers: J&J grew sales 6.6% YoY to $25B last quarter and has raised its dividend 64 straight years (+67% over 10 years). UnitedHealth’s dividend per share is up 271% over 10 years and is offered at a 2.26% current yield after a >50% drawdown, while McKesson’s dividend per share is up 193% over 10 years. Overall, it frames healthcare as a non-discretionary sector likely to support steadier returns through market downturns.

Analysis

This reads more like a factor screen than a fresh fundamental edge: the real trade is not “healthcare is safe,” but that investors are paying up for visibility as equity breadth narrows. In the next 2-6 weeks, that favors the highest-quality cash compounding balance sheets in the group, but the setup is not strong enough to justify chasing multiple expansion unless there is a broader market drawdown or a real rate reversal.

Relative winners are the names with the least earnings sensitivity to utilization and policy noise. MCK is the cleanest model because distributor economics are tied to prescription volume and working capital efficiency rather than claims trend; it should also benefit if hospitals/clinics restock into a softer macro backdrop. JNJ is steadier but already priced as a ballast asset, so upside is mostly defensive flow rather than earnings surprise.

UNH is the key debate: a “rebound” is only durable if medical cost trend and pricing discipline stop deteriorating. If not, the stock can bounce on sentiment while still underperforming over 3-6 months as margin assumptions get revised lower; that makes it more of a catalyst-trading vehicle than a true defensive compounder right now. The contrarian risk is that the market already knows healthcare is defensive, so the best entry point may be after a risk-off spike rather than on an article like this.

Bottom line: this is a modestly supportive read for XLV, MCK, and to a lesser extent JNJ, but the alpha is more in pair selection than outright longs. The highest-conviction path is to own the cleaner earnings visibility and avoid paying for a cyclical recovery story that still depends on claims normalization and regulatory stability.

Key Decisions for Investors

• Long MCK vs short UNH for 1-3 months: favor the distributor’s lower headline risk and more predictable pass-through economics; stop if UNH medical cost ratios stabilize for two consecutive prints or MCK guidance shows margin compression.
• Buy XLV on a broad market pullback, not at current levels: use it as a defensive hedge against growth multiple compression; fade the trade if XLV underperforms SPY by more than 3% over a month in a continued risk-on tape.
• Accumulation-only on JNJ over 6-12 months: treat it as portfolio insurance, not a momentum trade; the thesis breaks if the stock rerates above its historical defensive premium without an earnings step-up.
• Avoid initiating fresh UNH longs ahead of claims-data confirmation: wait for evidence that cost trend is normalizing and Medicare Advantage pricing is adequate; if not, the rebound is likely a bear-market rally within the stock.